EVALUATION OF TRANSITION EFFICACY TO ANGIOTENSINE CONVERTING ENZYME INHIBITORS IN PATIENTS WITH INSUFFICIENT BLOOD PRESSURE CONTROL. THE RESULTS FROM REGIONAL PROGRAM “SARA”

Abstract

Aim. To evaluate an additional antihypertension efficacy and tolerability of perindopril comparing to sartans in real clinical practice.Material and methods. The study had been designed, that included 208 patients. Main inculsion criteria was arterial hypertension (AH) with insufficient blood pressure (BP) control on treatment by angiotensine receptor blocker (ARB) as monotherapy, with 1 or 2 risk factors by SCORE system and on treatment by a free ARB combination with other drugs classes. In inclusion to program, instead of ARB perindopril (Prestarium A) 10 mg was added or its disperging form 10 mg in the morning. Duration of program lasted for 3 months. The evaluation of BP decrease was done, as the target BP levels reach and treatment response.Results. On treatment with perindopril, in 2 weeks there was statistically significant (p<0,05) decrease of BP, and this positive dynamics remained for all follow-up period. Target BP was reached in 42,4% patients. Assessment of efficacy criteria of SARA program revealed in all participants BP decrease from baseline level, with median of systolic BP decrease as 30 [25;42] mmHg, diastolic — 20 [10;20] mmHg. Target BP was reached in 42,4%.Conclusion. Transition from non-effective former sartans treatment to perindopril makes for successful BP control with high treatment tolerance. Such approach can be recommended for patient’s management in real clinical practice.

Keywords

• arterial hypertension
• prestarium a
• perindopril
• efficacy